Standard of care in immunotherapy trials: Challenges and considerations

References

• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12(4):278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Eng J Med 2012; 367(19):1783-91;PMID:23020162;http://dx.doi.org/10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47(2):115-23;PMID:20350658;http://dx.doi.org/10.1053/j.seminhematol.2010.01.011
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Eng J Med 2010; 363(5):411-22;PMID:20818862;http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng J Med 2012; 366(26):2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England) 2016; 387(10031):1909-20; PMID:26952546; http://dx.doi.org/10.1016/S0140-6736(16)00561-4
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu T-E, Bosquée L, Trigo JM, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15(1):59-68; PMID:24331154; http://dx.doi.org/10.1016/S1470-2045(13)70510-2
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17(6):822-35; PMID:27132212; http://dx.doi.org/10.1016/S1470-2045(16)00099-1
   PubMed Web of Science ®Google Scholar
• Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH. Advancing clinical trials to streamline drug development. Clin Cancer Res 2015; 21(20):4527-35; PMID:26473188; http://dx.doi.org/10.1158/1078-0432.CCR-15-0039
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010; 363:711-23; http://dx.doi.org/10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol 2016; [Epub ahead of print]; PMID:27769635; http://dx.doi.org/10.1016/j.ejso.2016.07.145
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Prolonged Survival in stage III Melanoma with Ipilimumab adjuvant therapy. N Eng J Med 2016; 375(19): 1845–1855; PMID:27717298; http://dx.doi.org/10.1056/NEJMoa1611299
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28(19):3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Eng J Med 2013; 369(2):134-44;PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 2016; 387(10027): 1540–1550; PMID:26712084; http://dx.doi.org/10.1016/s0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Eng J Med 2015; 373(2):123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Eng J Med 2015; 373(17):1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13(3):247-55; PMID:22341744; http://dx.doi.org/10.1016/S1470-2045(12)70063-3
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Eng J Med 2006; 355(24):2542-50;PMID:17167137;http://dx.doi.org/10.1056/NEJMoa061884
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11(6):521-9; PMID:20493771; http://dx.doi.org/10.1016/S1470-2045(10)70112-1
   PubMed Web of Science ®Google Scholar
• Perol M, Chouaid C, Perol D, Barlesi F, Gervais R, Westeel V, Crequit J, Lena H, Vergnenegre A, Zalcman G, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012; 30(28):3516-24; PMID:22949150; http://dx.doi.org/10.1200/JCO.2011.39.9782
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30(17):2046-54;PMID:22547592;http://dx.doi.org/10.1200/JCO.2011.38.4032
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cső szi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Eng J Med 2016; 375(19): 1823–1833; PMID:27718847; http://dx.doi.org/10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Bristol-myers squibb statement on top-line results from checkmate-026 5 August 2016 [accessed 15 September 2016]. http://news.bms.com/press-release/bristol-myers-squibb-announces-top-line-results-checkmate-026-phase-3-study-opdivo-niv
   Google Scholar
• Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19(1):21-34
   PubMed Web of Science ®Google Scholar
• Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (Oxford, England: 1990) 2011; 47(10):1476-83; PMID:21600759; http://dx.doi.org/10.1016/j.ejca.2011.04.030
   PubMed Web of Science ®Google Scholar
• Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 2006; 106(2):375-82; PMID:16342250; http://dx.doi.org/10.1002/cncr.21611
   PubMed Web of Science ®Google Scholar
• Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, et al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. Annal Oncol 2015; 26(11):2267-74; http://dx.doi.org/10.1093/annonc/mdv324
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Eng J Med 2011; 364(26):2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16(8):908-18; PMID:26115796; http://dx.doi.org/10.1016/S1470-2045(15)00083-2
   PubMed Web of Science ®Google Scholar
• Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr., Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4):375-84; PMID:25795410; http://dx.doi.org/10.1016/S1470-2045(15)70076-8
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Eng J Med 2015; 372(4):320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (London, England) 2014; 384(9948):1109-17; PMID:25034862;http://dx.doi.org/10.1016/S0140-6736(14)60958-2
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Eng J Med 2015; 372(26):2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Nishino M, Jagannathan JP, Krajewski KM, O'Regan K, Hatabu H, Shapiro G, Ramaiya NH. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 2012; 198(4):737-45;PMID:22451534;http://dx.doi.org/10.2214/AJR.11.7483
   PubMed Web of Science ®Google Scholar
• Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015; 33(31):3541-3; PMID:26261262; http://dx.doi.org/10.1200/JCO.2015.61.6870
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3):205-16; PMID:10655437; http://dx.doi.org/10.1093/jnci/92.3.205
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990) 2009; 45(2):228-47; PMID:19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15(23):7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
   PubMed Web of Science ®Google Scholar
• Mitchell PL, Quinn MA, Grant PT, Allen DG, Jobling TW, White SC, Zhao A, Karanikas V, Vaughan H, Pietersz G, et al. A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. J Immunother Cancer 2014; 2(16; PMID:24995129; http://dx.doi.org/10.1186/2051-1426-2-16
   PubMedGoogle Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Eng J Med 2011; 364(22):2119-27; PMID:21631324; http://dx.doi.org/10.1056/NEJMoa1012863
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (London, England) 2016; 387(10030): 1837–1846; http://dx.doi.org/10.1016/s0140-6736(16)00587-0
   Web of Science ®Google Scholar
• Chen TT. Statistical issues and challenges in immuno-oncology. J Immunother Cancer 2013; 1:18; PMID:24829754; http://dx.doi.org/10.1186/2051-1426-1-18
   PubMedGoogle Scholar
• Chen TT. Predicting analysis times in randomized clinical trials with cancer immunotherapy. BMC Med Res Methodol 2016; 16(12; PMID:26830911; http://dx.doi.org/10.1186/s12874-016-0117-3
   PubMed Web of Science ®Google Scholar
• Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 2016; 21(5):643-50; PMID:27026676; http://dx.doi.org/10.1634/theoncologist.2015-0498
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P, Pazdur R. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 2016; 21(5):634-42;PMID:26984449;http://dx.doi.org/10.1634/theoncologist.2015-0507
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall MA, Punt CJA, Haanen JB. Phase, III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-22; http://dx.doi.org/10.1200/jco.2012.44.6112
   PubMed Web of Science ®Google Scholar
• Gomella L, Nabhan C, DeVries T, Whitmore J, Frohlich M, George D. 683 estimating the overall survival benefit of sipuleucel-t in the impact trial accounting for crossover treatment in control subjects with autologous immunotherapy generated from cyropreserved cells. J Urol; 187(4):e278-e9; http://dx.doi.org/10.1016/j.juro.2012.02.765
   PubMed Web of Science ®Google Scholar
• Prasad V, Grady C. The misguided ethics of crossover trials. Contemp Clin Trials 2014; 37(2):167-9; PMID:24365533; http://dx.doi.org/10.1016/j.cct.2013.12.003
   PubMed Web of Science ®Google Scholar
• Chia PL, Do H, Morey A, Mitchell P, Dobrovic A, John T. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. Lung cancer (Amsterdam, Netherlands) 2016; 98:29-32; PMID:27393503
   PubMed Web of Science ®Google Scholar
• Xi L, Pham T, Payabyab EC, Sherry RM, Rosenberg SA, Raffeld M. Circulating Tumor DNA as an Early Indicator of Response to T-Cell Transfer Immunotherapy in Metastatic Melanoma. Clin Cancer Res 2016
   Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33(25):2780-8; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Eng J Med 2015; 373(1):23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Eng J Med 2015; 372; doi:10.1056/NEJMoa1414428
   Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17(11): 1497–1508; http://dx.doi.org/10.1016/s1470-2045(16)30498-3
   Web of Science ®Google Scholar
• Bendell J, Tae Won K, Cheng Ean C, Yung-Jue B, Lee C, Desai J, Lewin J, Wallin J, Das Thakur M, Mwawasi G, et al. LBA-01Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC). Annal Oncol 2016; 27(suppl 2):ii140
   Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Eng J Med 2015; 372(21):2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17(11): 1558–1568; http://dx.doi.org/10.1016/s1470-2045(16)30366-7
   Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Schadendorf D, Ferrucci PF, Smylie M, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). ASCO Meeting Abstracts 2016; 34(15_suppl):9505
   Google Scholar